TxCell develops cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases.
TxCell, a spin off of Inserm (France's National Institute for Health and Medical Research) located in the technology park of Sophia Antipolis, near Nice in southern France, is developing cell-based immuno-therapies for the treatment of severe chronic inflammatory diseases with high medical need using its unique and proprietary technology platform based on the properties of Type 1 regulatory T lymphocytes (Tr1 cells). The company has completed enrollment of a PhI/II study in refractory Crohn's disease patients and has reported first positive results. The company plans to initiate a PhIIb study in the same patientpopulation and bring a second product candidate into a PhI/II study in refractory rheumatoid arthritis patients.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Feb 24, 2017 | Post-IPO Equity | €11M | 1 | — | — | Detail |
Nov 26, 2012 | Series C | €12.40M | 1 | InnoBio Fund | — | Detail |
Feb 1, 2008 | Series B | €10.50M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
InnoBio Fund | — | Post-IPO Equity |
Bioam Gestion | — | Series B |